Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Virchows Archiv
Published in: Virchows Archiv 2/2017

01-02-2017 | Original Article

Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma

Authors: Ulrike Unger, Carsten Denkert, Ioana Braicu, Jalid Sehouli, Manfred Dietel, Sibylle Loibl, Silvia Darb-Esfahani

Published in: Virchows Archiv | Issue 2/2017

Login to get access

Abstract

HER3 is a member of the epidermal growth factor family and was predominantly described as a negative prognostic factor in various solid tumors as well as in ovarian cancer. In this study, we investigated HER3 on protein and mRNA expression in histologically defined subtypes of ovarian cancer looking for an influence on patient’s survival. Altogether, we examined HER3 in ovarian high-grade serous (HGSC, n = 320), low-grade serous (LGSC, n = 55), endometrioid (EC, n = 33), and clear cell (CCC, n = 48) carcinomas using immunohistochemistry (IHC) and quantitative real-time reverse transcription PCR (qRT-PCR). Univariate and multivariate analyses were performed to explore the association between HER3 and overall survival (OS) as well as progression-free survival (PFS). In HGSC, high HER3 mRNA expression was a favorable prognostic factor for PFS (P = 0.008) and OS (P = 0.052), while for high HER3 protein expression, a trend towards better survival was seen (OS P = 0.064; PFS P = 0.099). A subgroup of HGSC with negative HER3 staining and negative HER3 mRNA levels showed most unfavorable OS and PFS (P = 0.002 and P = 0.004, respectively). Using the multivariate Cox regression model, HER3 was predictive for prolonged PFS (HR, 0.48; 95% CI, 0.26–0.88; P = 0.018). All in all, we cannot confirm the reported negative prognostic impact of HER3 expression in high-grade serous ovarian carcinoma and moreover find a rather positive prognostic implication of HER3 in this major ovarian cancer histological subtype.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Miller K, Jemal A (2015) Cancer statistics, 2015. CA Cancer J Clin 65(1):21254CrossRef
2.
3.
Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Krebs in Deutschland 2009/2010. 2013;(9):84–7.
4.
Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study. J Clin Oncol [Internet]. 21(17):3194–3200. doi:10.​1200/​JCO.​2003.​02.​153 CrossRefPubMed
5.
Howlader N, Noone AA, Krapcho M, Garshell J, Miller D, Altekruse S, et al. (2015) National Cancer Institute SEER Cancer Statistics Review 1975–2010. Natl Cancer Inst
6.
Kita YA, Barff J, Luob Y, Wenb D, Brankowb D, Hub S, et al. (1994) NDF / heregulin stimulates the phosphorylation of Her3 / erbB3. 349:139–43
7.
Carraway KL, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M et al (1997) Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 387:512–516CrossRefPubMed
8.
Sliwkowskiso MX, Schaefers G, Akita W, Lofgrens JA, Fitzpatricks, VD, Nuijenss A, et al. (1994) Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin. 269(20):14661–5
9.
Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS et al (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell [Internet] Elsevier Ltd 15(5):429–440. doi:10.​1016/​j.​ccr.​2009.​03.​020 CrossRef
10.
Olayioye MA, Neve, RM, Lane H A, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19(13):3159–3167.
11.
Liang J, Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2(4):336–342CrossRef
12.
Steffensen KD, Waldstrøm M, Andersen RF, Olsen DA, Jeppesen U, Knudsen HJ, et al. (2008) Protein levels and gene expressions of the epidermal growth factor receptors , HER1 , HER2 , HER3 and HER4 in benign and malignant ovarian tumors. Int J Oncol. 195–204
13.
14.
Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS et al (2010) Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol [Internet] 28(7):1215–1223. doi:10.​1200/​JCO.​2009.​22.​3354 CrossRef
15.
Kaye SB, Poole CJ, Dańska Bidzińska A, Gianni L, Del Conte G, Gorbunova V et al (2013) A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol 24(1):148–152CrossRef
16.
Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C et al (2008) Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med 5(12):1749–1760CrossRef
17.
Kurman RJ, Carcangiu ML, Herrington CS (2014) WHO Classification of Tumours of Female Reproductive Organs. Lyon Int Agency Res Cancer
18.
Darb-Esfahani S, Wirtz RM, Sinn BV, Budczies J, Noske A, Weichert W et al (2009) Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue. Endocr Relat Cancer 16(4):1229–1239CrossRefPubMed
19.
20.
Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD et al (2010) Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol United States 29(3):203–211CrossRef
21.
Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller DGC (2005) Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. Int J Gynecol Pathol 24(2):147–152CrossRefPubMed
22.
Davies S, Holmes A, Lomo L et al (2014) High incidence of ErbB3, ErbB4 and MET expression in ovarian cancer. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol 33(4):402–410CrossRef
23.
Li L, Zhong Y-P, Zhang W, Zhang J-Q, Yao Z-Q (2004) Relationship of expression of C-erbB2, C-erbB3, and C-erbB4 with ovarian carcinoma. Chin J Cancer 23(5):568–572
24.
Leng J, Lang J, Shen KGL (1997) Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary. Chinese Med Sci J 12(2):67–70
25.
Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J et al (2008) High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res 14(23):7843–7849CrossRefPubMed
26.
Witton CJ, Reeves JR, Going JJ, Cooke TG, Barlett JMS (2003) Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200(3):290–297CrossRefPubMed
27.
Hirakawa T, Nakata B, Amano R, Kimura K, Shimizu S, Ohira G et al (2011) HER3 overexpression as an independent indicator of poor prognosis for patients with curatively resected pancreatic cancer. Oncology 81:192–198CrossRefPubMed
28.
Baiocchi G, Lopes A, Coudry RA, Rossi BM, Soares FA, Aguiar S et al (2009) ErbB family immunohistochemical expression in colorectal cancer patients with higher risk of recurrence after radical surgery. Int J Color Dis 24(9):1059–1068CrossRef
29.
Köbel M, Kalloger SE, Carrick J, Huntsman D, Asad H, Oliva E et al (2009) A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am J Surg Pathol [Internet] 33(1):14–21. doi:10.​1097/​PAS.​0b013e3181788546​ CrossRef
30.
Heim D, Budczies J, Stenzinger A, Treue D, Hufnagl P, Denkert C et al (2014) Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. Int J Cancer 135(10):2362–2369CrossRefPubMed
31.
Bae SY, La Choi Y, Kim S, Kim M, Kim J, Jung SP et al (2013) HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients. Breast Cancer Res Treat 139(3):741–750CrossRefPubMed
32.
Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, et al. (2015) Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial. ASCO Annual Meeting, Chicago, abstract#5504
Metadata
Title
Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma
Authors
Ulrike Unger
Carsten Denkert
Ioana Braicu
Jalid Sehouli
Manfred Dietel
Sibylle Loibl
Silvia Darb-Esfahani
Publication date
01-02-2017
Publisher
Springer Berlin Heidelberg
Published in
Virchows Archiv / Issue 2/2017
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-016-2050-6

Other articles of this Issue 2/2017

Virchows Archiv 2/2017 Go to the issue

Original Article

Epstein–Barr virus infection and gene promoter hypermethylation in rheumatoid arthritis patients with methotrexate-associated B cell lymphoproliferative disorders

ACKNOWLEDGEMENT TO REVIEWERS

Thanks to you

Brief Report

Follicular lymphoma with rosette formation with an exclusive diffuse pattern

News

In this issue

Original Article

The enteric nervous system and the musculature of the colon are altered in patients with spina bifida and spinal cord injury

Original Article

Endoscopic submucosal dissection specimens in early colorectal cancer: lateral margins, macroscopic techniques, and possible pitfalls